Patents by Inventor Tetsuya Suhara

Tetsuya Suhara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220133698
    Abstract: The present invention provides an ?-synuclein aggregate binding agent that has high binding selectivity for an ?-synuclein aggregate. The ?-synuclein aggregate binding agent contains a compound represented by a formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: in the formula (I), R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; the ring A is a benzene or pyridine ring; the ring B is represented by the following formula (i) or (ii): R4 and R5 are each independently selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 5, 2022
    Inventors: Makoto Higuchi, Maiko Ono, Tetsuya Suhara, Meiei Cho
  • Publication number: 20220056020
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Application
    Filed: September 16, 2021
    Publication date: February 24, 2022
    Inventors: Makoto HIGUCHI, Tetsuya SUHARA, Masahiro MARUYAMA, Meiei CHO, Hitoshi SHIMADA
  • Publication number: 20210275696
    Abstract: The purpose of the present invention is to provide a technique for imaging the brain of a live animal and application of the technique. A radiolabeled dibenzoazepine derivative, which shows excellent brain parmeability, high receptor selectivity and high quantitativity, is used for imaging a live animal body. A dibenzoazepine derivative is used for treating a disease in which hM4D receptor or hM3D receptor participates. Further, a radiolabeled dibenzoazepine derivative is used for imaging an axonal end which is innervated by a nerve cell.
    Type: Application
    Filed: June 21, 2019
    Publication date: September 9, 2021
    Applicant: National Institutes for Quantum and Radiological Science and Technology
    Inventors: Takafumi MINAMIMOTO, Yuji NAGAI, Bin JI, Naohisa MIYAKAWA, Makoto HIGUCHI, Tetsuya SUHARA
  • Publication number: 20200262829
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and [Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Application
    Filed: February 21, 2020
    Publication date: August 20, 2020
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • Patent number: 10604516
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: March 31, 2020
    Assignee: National Institutes for Quantum and Radiological Science and Technology
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • Patent number: 10335503
    Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.
    Type: Grant
    Filed: July 5, 2016
    Date of Patent: July 2, 2019
    Assignee: Public University Corporation Yokohama City University
    Inventors: Takuya Takahashi, Tomoyuki Miyazaki, Tetsuya Suhara, Makoto Higuchi, Meiei Cho
  • Patent number: 10041954
    Abstract: The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free ? immunoglobulin chains and free ? immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free ? immunoglobulin chains, free ? immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: August 7, 2018
    Assignee: RESVO INC.
    Inventors: Arata Ohnishi, Takafumi Minamimoto, Tetsuya Suhara
  • Publication number: 20180200391
    Abstract: The present invention provides a compound represented by formula (I), a pharmaceutically acceptable salt thereof or a solvate thereof. (In the formula, each of A and Z independently represents CO, SO or SO2; each of X and Y independently represents S or O; each of R1-R4 independently represents a hydrogen atom, an alkyl group, an alkenyl group, an alkynyl group or a halogen group; each R5 independently represents an alkyl group, an alkenyl group, an alkynyl group or a halogen group; and n represents an integer of 0-4.) This compound is capable of specifically binding to an AMPA receptor, and shows extremely high brain uptake.
    Type: Application
    Filed: July 5, 2016
    Publication date: July 19, 2018
    Applicant: Public University Corporation Yokohama City University
    Inventors: Takuya Takahashi, Tomoyuki Miyazaki, Tetsuya Suhara, Makoto Higuchi, Meiei Cho
  • Publication number: 20180120328
    Abstract: The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free ? immunoglobulin chains and free ? immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free ? immunoglobulin chains, free ? immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects.
    Type: Application
    Filed: July 10, 2017
    Publication date: May 3, 2018
    Inventors: Arata OHNISHI, Takafumi MINAMIMOTO, Tetsuya SUHARA
  • Patent number: 9382303
    Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.
    Type: Grant
    Filed: December 30, 2014
    Date of Patent: July 5, 2016
    Assignees: KYOTO UNIVERSITY, NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES
    Inventors: Haruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
  • Publication number: 20160131663
    Abstract: The purpose of the present invention is to provide: a biomarker for psychiatric and neurological disorders, in particular, a biomarker for diagnosing psychiatric and neurological disorders; and a test kit and test method for psychiatric and neurological disorders. The inventors discovered that there is a significant increase in the concentration of free ? immunoglobulin chains and free ? immunoglobulin chains in the blood samples from patients with psychiatric and neurological disorders. Consequently, the present invention provides a biomarker for psychiatric and neurological disorders that includes at least one selected from the group consisting of free ? immunoglobulin chains, free ? immunoglobulin chains, and fragments thereof. Using this biomarker for psychiatric and neurological disorders enables the psychiatric and neurological disorders to be easily tested and diagnosed with the blood samples from the subjects.
    Type: Application
    Filed: March 18, 2014
    Publication date: May 12, 2016
    Inventors: Arata OHNISHI, Takafumi MINAMIMOTO, Tetsuya SUHARA
  • Publication number: 20160045625
    Abstract: A compound selected from the group consisting of compounds represented by the formulas below or pharmaceutically acceptable salt thereof is useful in PET imaging for AMPA receptor.
    Type: Application
    Filed: April 2, 2014
    Publication date: February 18, 2016
    Inventors: Norihito Oi, Noboru Yamamoto, Michiyuki Suzuki, Yosuke Nakatani, Tetsuya Suhara, Meiei Cho, Toshimitsu Fukumura, Makoto Higuchi, Takafumi Minamimoto, Jun Maeda, Masaki Tokunaga, Yuji Nagai
  • Publication number: 20150266937
    Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phospholylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.
    Type: Application
    Filed: December 30, 2014
    Publication date: September 24, 2015
    Applicants: National Institute of Radiological Sciences, Kyoto University
    Inventors: Haruhisa INOUE, Hiroki TAKEUCHI, Ryosuke TAKAHASHI, Makoto HIGUCHI, Bin JI, Tetsuya SUHARA
  • Publication number: 20150239878
    Abstract: The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrogen, alkyl, alkenyl, acyl, and hydroxyalkyl; R3 is hydrogen or halogen; ring A is a benzene ring or a pyridine ring; ring B is selected from the group consisting of the following formulas (i), (ii), (iii), and (iv): in the formula (ii), Ra is alkyl; R4 and R5 are each separately selected from the group consisting of hydrogen, hydroxy, alkoxy, haloalkoxy, halohydroxyalkoxy, and aminoalkyl; and ??[Formula 3] represents a double bond or a triple bond. The above compound can be used as a molecular probe for imaging tau proteins that accumulate in the brain.
    Type: Application
    Filed: December 21, 2012
    Publication date: August 27, 2015
    Inventors: Makoto Higuchi, Tetsuya Suhara, Masahiro Maruyama, Meiei Cho, Hitoshi Shimada
  • Patent number: 8945576
    Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: February 3, 2015
    Assignees: Kyoto University, National Institute of Radiological Sciences
    Inventors: Haruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
  • Publication number: 20130189289
    Abstract: This invention relates to a vaccine for preventing or treating tautopathy, comprising a vector, as an active ingredient, comprising a nucleic acid encoding a mutant tau protein linked to a secretion signal sequence, wherein the vaccine is capable of inducing an antibody against an (optionally phosphorylated) tau protein in a subject in a more sustained manner compared with a case where the mutant tau protein is administered directly.
    Type: Application
    Filed: January 11, 2011
    Publication date: July 25, 2013
    Applicants: NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES, KYOTO UNIVERSITY
    Inventors: Haruhisa Inoue, Hiroki Takeuchi, Ryosuke Takahashi, Makoto Higuchi, Bin Ji, Tetsuya Suhara
  • Publication number: 20100111838
    Abstract: Brain-localizing polypeptides carrying a reactive group for linking to a molecule that does not have brain-localizing activity were successfully produced by introducing at least two lysine residues into cyclized polypeptides having a brain-localizing motif sequence. These polypeptides have improved metabolic stability compared to conventional brain-localizing polypeptides, and can efficiently translocate desired molecules into the brain.
    Type: Application
    Filed: February 27, 2008
    Publication date: May 6, 2010
    Applicants: Proteus Sciences Co., Ltd, National Institute of Radiological Sciences
    Inventors: Tomohiro Nakajo, Hirotaka Hara, Kazumasa Yamamoto, Hiromi Suzuki, Makoto Sawada, Tetsuya Suhara, Makoto Higuchi, Terushi Haradahira, Hin Ki
  • Publication number: 20100055036
    Abstract: The present invention relate to a method for monitoring a response to a therapy on a mammal having a neurodegenerative or neuroinflammatory disorder. According to a preferred embodiment, the method comprising the steps of: a) imaging the mammal using a radio-labeled peripheral benzodiazepine receptor ligand; b) administrating in the mammal at least one anti-amyloid or anti-neuroinflammatory agent; c) imaging the mammal of step b) using a radio-labeled peripheral benzodiazepine receptor ligand; and d) detecting the level of CNS neuroinflammation by the signals from the radio-labeled peripheral benzodiazepine receptor ligand.
    Type: Application
    Filed: March 12, 2008
    Publication date: March 4, 2010
    Applicant: National Institute of Radiolotgical Sciences
    Inventors: Tetsuya Suhara, Kazutoshi Suzuki, Makoto Higuchi, Ming-Rong Zhang, Jun Maeda, Bin Ji
  • Publication number: 20090234162
    Abstract: A radioactive halogen-labeled phenyoxyaniline derivative represented by the following formula: wherein R1 represents a group such as an alkyl group; X1, X2, X3 and X4 represent each a hydrogen atom, an alkyl group, an alkoxy group, an alkoxy group carrying 11C introduced thereinto or a radioactive halogen atom, provided that at least one of X1, X2, X3 and X4 represents an alkoxy group carrying 11C introduced thereinto or a radioactive halogen atom; which is a compound useful as a PBR ligand having a high affinity and a high selectivity. In in vitro measurement of PBR, a PBR ligand having a high affinity and a high selectivity is labeled with a radioactive halogen nuclear species so as to enable the measurement of PBR in vivo with the use of means including not only PET but also SPECT. Thus, a compound which is useful in early diagnosing, preventing and treating diseases such as Alzheimer type dementia can be obtained.
    Type: Application
    Filed: December 28, 2005
    Publication date: September 17, 2009
    Applicants: Taisho Pharmaceutical Co., Ltd., National Institute of Radiological Sciences
    Inventors: Kazutoshi Suzuki, Tetsuya Suhara, Christer Halldin, Ming-Rong Zhang, Atsuro Nakazato
  • Patent number: 6870069
    Abstract: A phenyloxyaniline derivative useful as a ligand for peripheral benzodiazepine receptor having a strong affinity and a high selectivity, which is represented by formula (1): wherein X1 and X2 are same or different and each is hydrogen atom or halogen atom; R1 and R2 are same or different and each is hydrogen atom, an alkyl group having 1 to 10 carbon(s) or a halogen-substituted alkyl group having 1 to 10 carbon(s); and R3 is a halogen-substituted alkyl group having 1 to 5 carbon(s), or a radioisotope thereof.
    Type: Grant
    Filed: November 4, 2003
    Date of Patent: March 22, 2005
    Assignees: National Institute of Radiological Sciences, Taisho Pharmaceutical Co., Ltd., Nihon Nohyaku Co., Ltd.
    Inventors: Kazutoshi Suzuki, Ming-Rong Zhang, Tetsuya Suhara, Atsuro Nakazato, Makoto Goto